Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Clopidogrel bisulfate
16 general benefit · 3 not a benefit
Apo-Clopidogrel · DIN 02252767 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Clopidogrel · DIN 02252767
Manufacturer: Apotex Inc.; listing date 2012-01-19
Health Canada: Marketed since 2011-12-19 · brand APO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252767)
Source record
DIN 02252767: Apo-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id APX
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252767
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73770
Interchangeable products
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: active shortage (reported September 29, 2026, estimated to end October 30, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02252767
Shortage record checked October 6, 2026
Auro-Clopidogrel · DIN 02416387 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Clopidogrel · DIN 02416387
Manufacturer: Auro Pharma Inc.; listing date 2014-04-30
Health Canada: Marketed since 2014-02-06 · brand AURO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416387)
Source record
DIN 02416387: Auro-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id AUR
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416387
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90094
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended September 13, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416387
Shortage record checked October 6, 2026
Bio-Clopidogrel · DIN 02444895 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Bio-Clopidogrel · DIN 02444895
Manufacturer: Biomed Pharma; listing date 2026-07-31
Health Canada: Marketed since 2023-08-02 · brand BIO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordBio-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02444895)
Source record
DIN 02444895: Bio-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id BMP
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02444895
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93012
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02444895
Shortage record checked October 6, 2026
Clopidogrel · DIN 02385813 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Clopidogrel · DIN 02385813
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2012-06-11 · brand CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordClopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02385813)
Source record
DIN 02385813: Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id SIV
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02385813
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87143
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended April 9, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385813
Shortage record checked October 6, 2026
Clopidogrel · DIN 02400553 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Clopidogrel · DIN 02400553
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Marketed since 2026-09-10 · brand CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordClopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02400553)
Source record
DIN 02400553: Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id SAI
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02400553
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88535
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended February 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02400553
Shortage record checked October 6, 2026
Jamp-Clopidogrel · DIN 02415550 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Clopidogrel · DIN 02415550
Manufacturer: Jamp Pharma Corporation; listing date 2014-07-30
Health Canada: Marketed since 2014-01-15 · brand JAMP-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02415550)
Source record
DIN 02415550: Jamp-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id JPC
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02415550
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90014
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended August 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02415550
Shortage record checked October 6, 2026
M-Clopidogrel · DIN 02502283 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Clopidogrel · DIN 02502283
Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30
Health Canada: Marketed since 2020-11-03 · brand M-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordM-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02502283)
Source record
DIN 02502283: M-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id MAT
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502283
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99186
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended February 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502283
Shortage record checked October 6, 2026
Mar-Clopidogrel · DIN 02422255 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Clopidogrel · DIN 02422255
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-06-26
Health Canada: Marketed since 2023-06-14 · brand MAR-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMar-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02422255)
Source record
DIN 02422255: Mar-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id MAR
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02422255
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90695
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended April 13, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02422255
Shortage record checked October 6, 2026
Mint-Clopidogrel · DIN 02408910 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Clopidogrel · DIN 02408910
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-09-27
Health Canada: Marketed since 2023-03-29 · brand MINT-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02408910)
Source record
DIN 02408910: Mint-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id MIN
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02408910
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89366
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended April 4, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408910
Shortage record checked October 6, 2026
NRA-Clopidogrel · DIN 02482037 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Clopidogrel · DIN 02482037
Manufacturer: Nora Pharma; listing date 2020-06-30
Health Canada: Marketed since 2020-03-05 · brand NRA-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02482037)
Source record
DIN 02482037: NRA-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id NRA
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02482037
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97237
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02482037
Shortage record checked October 6, 2026
PMS-Clopidogrel · DIN 02348004 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Clopidogrel · DIN 02348004
Manufacturer: Pharmascience Inc.; listing date 2012-02-29
Health Canada: Marketed since 2011-12-14 · brand PMS-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02348004)
Source record
DIN 02348004: PMS-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id PMS
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02348004
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83336
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended October 1, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02348004
Shortage record checked October 6, 2026
Plavix · DIN 02238682 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: RxHelp ONE lists PLAVIX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Plavix · DIN 02238682
Manufacturer: Sanofi Aventis Pharma; listing date 2003-09-04
Health Canada: Marketed since 2007-04-10 · brand PLAVIX · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238682)
Source record
DIN 02238682: Plavix
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id SAV
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $2.9350; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238682
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62114
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended December 11, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238682
Shortage record checked October 6, 2026
Ran-Clopidogrel · DIN 02379813 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Clopidogrel · DIN 02379813
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2012-06-26
Health Canada: Marketed since 2026-09-09 · brand SPC-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRan-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02379813)
Source record
DIN 02379813: Ran-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id RAN
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02379813
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86568
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended May 23, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02379813
Shortage record checked October 6, 2026
Teva-Clopidogrel · DIN 02293161 · 75 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Clopidogrel · DIN 02293161
Manufacturer: Teva Canada Limited; listing date 2012-02-29
Health Canada: Marketed since 2011-12-14 · brand TEVA-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02293161)
Source record
DIN 02293161: Teva-Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id TEV
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02293161
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77854
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Shortage status: shortage reported ended July 31, 2026 (report last updated July 31, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02293161
Shortage record checked October 6, 2026
Apo-Clopidogrel · DIN 02398591 · 300 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Apo-Clopidogrel · DIN 02398591
Manufacturer: Apotex Inc.; listing date 2013-06-27
Health Canada: Marketed since 2013-01-21 · brand APO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 300 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02398591)
Source record
DIN 02398591: Apo-Clopidogrel
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000663; group id 906; item number 2169; lccId None; manufacturer id APX
Source form: Tab; strength: 300mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $9.5447; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02398591
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88354
Interchangeable products
Plavix · DIN 02330555 · not recorded
Teva-Clopidogrel · DIN 02388065 · not recorded
Shortage status: active shortage (reported September 1, 2026, estimated to end October 30, 2026, last updated September 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02398591
Shortage record checked October 6, 2026
Teva-Clopidogrel · DIN 02388065 · 300 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Teva-Clopidogrel · DIN 02388065
Manufacturer: Teva Canada Limited; listing date 2012-08-27
Health Canada: Marketed since 2013-01-02 · brand TEVA-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 300 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02388065)
Source record
DIN 02388065: Teva-Clopidogrel
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000663; group id 906; item number 2169; lccId None; manufacturer id TEV
Source form: Tab; strength: 300mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $9.5447; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02388065
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87363
Interchangeable products
Apo-Clopidogrel · DIN 02398591 · not recorded
Plavix · DIN 02330555 · not recorded
Shortage status: shortage reported ended May 5, 2026 (report last updated May 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388065
Shortage record checked October 6, 2026
Co Clopidogrel · DIN 02303027 · 75 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-29 — choose a marketed DIN from the same-category list.Discontinued April 29, 2025 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-29 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-29 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Co Clopidogrel · DIN 02303027
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-01-19
Health Canada: Cancelled post market since 2025-04-29 · brand ACT CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCo Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02303027)
Source record
DIN 02303027: Co Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id COB
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02303027
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78834
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Sandoz Clopidogrel · DIN 02359316 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: discontinued (February 28, 2018, reported by ACTAVIS PHARMA COMPANY); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02303027
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 29, 2025 — choose a marketed DIN from the same-category list.
Sandoz Clopidogrel · DIN 02359316 · 75 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2021-06-28 — choose a marketed DIN from the same-category list.Discontinued June 28, 2021 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-06-28 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-06-28 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Clopidogrel · DIN 02359316
Manufacturer: Sandoz Canada Inc.; listing date 2012-02-29
Health Canada: Cancelled post market since 2021-06-28 · brand SANDOZ CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02359316)
Source record
DIN 02359316: Sandoz Clopidogrel
Raw flags: sec3=Y
Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id SDZ
Source form: Tab; strength: 75mg
Recorded listing: General benefit
Source prices (unrounded): $0.2631; ministry $0.2631
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02359316
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84434
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631
Auro-Clopidogrel · DIN 02416387 · $0.2631
Bio-Clopidogrel · DIN 02444895 · $0.2631
Clopidogrel · DIN 02385813 · $0.2631
Clopidogrel · DIN 02400553 · $0.2631
Co Clopidogrel · DIN 02303027 · $0.2631
Jamp-Clopidogrel · DIN 02415550 · $0.2631
M-Clopidogrel · DIN 02502283 · $0.2631
Mar-Clopidogrel · DIN 02422255 · $0.2631
Mint-Clopidogrel · DIN 02408910 · $0.2631
NRA-Clopidogrel · DIN 02482037 · $0.2631
PMS-Clopidogrel · DIN 02348004 · $0.2631
Plavix · DIN 02238682 · $0.2631
Ran-Clopidogrel · DIN 02379813 · $0.2631
Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended June 28, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02359316
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 28, 2021 — choose a marketed DIN from the same-category list.
Plavix · DIN 02330555 · 300 mg · tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-10 — choose a marketed DIN from the same-category list.Discontinued December 10, 2020 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-12-10 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Savings card: RxHelp ONE lists PLAVIX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Plavix · DIN 02330555
Manufacturer: Sanofi Aventis Pharma; listing date 2012-08-27
Health Canada: Cancelled post market since 2020-12-10 · brand PLAVIX · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 300 MG · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPlavix: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02330555)
Source record
DIN 02330555: Plavix
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000663; group id 906; item number 2169; lccId None; manufacturer id SAV
Source form: Tab; strength: 300mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02330555
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81628
Interchangeable products
Apo-Clopidogrel · DIN 02398591 · not recorded
Teva-Clopidogrel · DIN 02388065 · not recorded
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02330555
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 10, 2020 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (B01AC): coverage varies; not interchangeable
- Ticlopidine (Ticlid): limited Use 219, 220, 221, not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered
Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE
Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL
92:00 UNCLASSIFIED THERAPEUTIC AGENTS
· 2 products · Listed, not a benefit (1),
Limited Use, codes 219, 220, 221 (1) · strengths: 250mg · Tab
· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab
· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab
· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab
· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L
· 3 products · General benefit · strengths: 50mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab
· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L
· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk
· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk
· 16 products · General benefit · strengths: 10mg, 20mg · Tab
· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00
and 78 more
Full class listing
Related classes:
Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Availability
Apo-Clopidogrel · DIN 02252767
Shortage status: active shortage (reported 2026-09-29, estimated to end 2026-10-30, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02252767
Check this DIN againTeva-Clopidogrel · DIN 02293161
Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02293161
Check this DIN againApo-Clopidogrel · DIN 02398591
Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-10-30, last updated 2026-09-04); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02398591
Check this DIN againTeva-Clopidogrel · DIN 02388065
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388065
Check this DIN againCo Clopidogrel · DIN 02303027
Shortage status: discontinued (2018-02-28, reported by ACTAVIS PHARMA COMPANY); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02303027
Check this DIN againPlavix · DIN 02330555
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02330555
Check this DIN again